An Open Label, Randomized, comparison of the Immunogenicity and Safety of Wockhardts Human Insulin Basal Bolus Regimen {Intensified Conventional Insulin Therapy with Soluble Insulin and Isophane Insulin (Wosulin R, Wosulin N and Wosulin 70/30)} with the Novo Nordisk?s yeast based Human Insulin Basal Bolus Regimens, marketed in United States (Novolin R, Novolin N and Novolin 70/30) in Type 1 Diabetics.

Trial Profile

An Open Label, Randomized, comparison of the Immunogenicity and Safety of Wockhardts Human Insulin Basal Bolus Regimen {Intensified Conventional Insulin Therapy with Soluble Insulin and Isophane Insulin (Wosulin R, Wosulin N and Wosulin 70/30)} with the Novo Nordisk?s yeast based Human Insulin Basal Bolus Regimens, marketed in United States (Novolin R, Novolin N and Novolin 70/30) in Type 1 Diabetics.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Insulin (Primary) ; Insulin suspension isophane (Primary) ; Insulin suspension isophane/insulin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Mar 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 04 Mar 2013 Planned End Date changed from 1 Mar 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top